Introduction
Nearly 50% of patients with chronic graft-versus-host disease (GVHD) receive second-line systemic treatment within the first year after initial systemic treatment due to inadequate control of GVHD, 1, 2 but no standard second-line treatment has been established. Many different agents have been used, and despite high response rates reported in the literature, actual experience with available agents tends to be unsatisfying. 3, 4 New therapies for chronic GVHD are likely to be tested initially for second-line treatment. [5] [6] [7] The lack of validated and standardized response criteria represents a major obstacle in designing clinical trials and interpreting the results. [8] [9] [10] [11] In a review of 60 published studies of second-line treatment for chronic GVHD during the past 20 years, 6 only one report clearly described a formal statistical hypothesis based on an historical success rate. 12 The absence of data that could be used as a reliable and meaningful basis for the null hypothesis has made it impossible to design robust clinical trials with prespecified statistical considerations. 6 In clinical trials testing investigational products for treatment of chronic GVHD, causes of failure after second-line treatment can be categorized into 3 types of events: nonrelapse mortality, recurrent malignancy and systemic treatment change (i.e., initiation of third-line systemic treatment). 5 We hypothesized that failure-free survival (FFS) defined as the absence of these failures is a meaningful clinical metric that could be used as a shorter-term success endpoint for clinical trials. Furthermore, we hypothesized that incorporation of an upper limit of the steroid dose at the time of assessment could be used as an additional criterion to enhance the clinical benefit associated with FFS by indicating that GVHD has been well controlled and by decreasing the risk of steroid-related adverse effects. 6, 9 We also hypothesized that lower steroid doses at the time of endpoint assessment may be associated with higher rates of subsequent successful withdrawal of all immunosuppressive treatment after resolution of GVHD.
For personal use only. on April 14, 2017 . by guest www.bloodjournal.org From This study had 4 aims: (1) to characterize causes of treatment failure after second-line treatment for chronic GVHD in consecutive patients representing those who would likely be eligible for future phase II trials, (2) to elucidate prognostic factors associated with treatment failure, (3) to compare rates of withdrawal of all immunosuppressive treatment during secondline treatment according to steroid doses at 6 months and (4) to provide shorter-term success rates either without or with an upper limit of the steroid dose at 6 months. We propose that these success rates could be used to design and evaluate future phase II studies of second-line treatment for chronic GVHD.
Patients and methods

Patients and data collection
Between January 2001 and February 2011, 425 consecutive relapse-free patients at the Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance received second-line systemic treatment for chronic GVHD due to progression or lack of improvement. In order to mimic the characteristics of patients likely to be enrolled in future phase II trials of second-line treatment for chronic GVHD, 312 of these 425 patients who met all of the following criteria were selected for inclusion in the study cohort: (1) patients who had already received systemic steroid treatment for chronic GVHD at a prednisone-equivalent dose of at least 0.5 mg/kg/day before second-line treatment, (2) patients who were under systemic immunosuppressive treatment when second-line treatment was started, (3) patients who received second-line treatment due to progressive GVHD manifestations after at least one week of initial treatment or due to lack of improvement after at least two weeks of initial treatment. Patients were enrolled regardless of the indication for transplantation, the conditioning regimen, graft source, donor relationship or HLA-matching between the donor and recipient. The following patients were excluded: (1) patients who did not receive prednisone-equivalent steroid dose ≥ 0.5 mg/kg/day before secondFor personal use only. on April 14, 2017 . by guest www.bloodjournal.org From line treatment (n=64), (2) patients who were not taking any systemic treatment at the start of second-line treatment (n=35), (3) patients with progressive GVHD who started second-line treatment after less than 7 days of initial treatment (n=2) or after a very rapid taper of initial prednisone treatment (n=2), and patients with lack of improvement who started second-line treatment after less than 14 days of initial treatment (n=10).
Involved sites, types of treatment, dates and the reasons for change of treatment (progression or lack of improvement) after the initial systemic treatment for chronic GVHD were recorded prospectively. 1 The values of platelet count, serum total bilirubin, steroid doses and the NIH global score of chronic GVHD immediately before second-line treatment were collected from medical records. Steroid doses at 6 months were also recorded as part of the assessment after second-line treatment. All patients had given written consent allowing the use of medical records for research in accordance with the Declaration of Helsinki, and the Institutional Review
Board approved the study.
Definitions
Chronic GVHD was defined by the NIH consensus criteria. 13 Lung involvement was defined according to the NIH criteria for bronchiolitis obliterans. 14 Liver involvement was defined as an NIH liver score ≥ 1, where serum transaminase, alkaline phosphatase and bilirubin concentrations were all taken into account. Second-line treatment was defined as any additional systemic treatment not used for initial treatment of chronic GVHD. An increase in steroid dose was not considered as second-line treatment, since temporarily increased steroid doses and resumption of steroid treatment are often necessary during the initial treatment of chronic GVHD. 15 This definition of treatment change corresponds to the anticipated situation of future patients who would be candidates for a clinical trial testing an investigational product for treatment of "steroid-resistant" or "steroid-refractory" chronic GVHD. Similarly, third-line
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Failure-free survival (FFS) was defined by the absence of third-line treatment, nonrelapse mortality and recurrent malignancy during second-line treatment. Recurrent malignancy was defined by hematologic relapse or any unplanned intervention to prevent progression of malignancy in patients with molecular, cytogenetic, flow cytometric or any other evidence of malignant disease after transplantation. An accelerated taper of immunosuppressive treatment due to evidence of recurrent disease was considered as an unplanned intervention and categorized as recurrent malignancy. Withdrawal of all systemic immunosuppressive treatment was defined as described previously.
15
Treatment of chronic GVHD
At our center, initial systemic treatment for chronic GVHD is generally addition of prednisone to any other immunosuppressive agents the patient is already taking. 16, 17 Prednisone was most often administered initially at a dose of 1 mg/kg once daily for 2 weeks, and the dose was tapered during the subsequent 4 weeks to 1 mg/kg every other day as allowed by improvement in GVHD manifestations. After resolution of reversible manifestations of chronic GVHD, systemic treatment was gradually withdrawn. Decisions to initiate second-line or subsequent treatment were made at the discretion of the attending physician.
Statistical analysis
Cumulative incidence estimates of recurrent malignancy, nonrelapse mortality and treatment change as causes of failure during second-line treatment were derived, treating each event as a competing risk for the other two. 18 Successful withdrawal of all immunosuppressive treatment during second-line treatment after resolution or improvement of all reversible manifestations of GVHD was treated as a competing risk for all 3 types of failure. Rates of FFS were estimated by
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Factors having a likelihood ratio P-value
≤
.05 for association with failure in univariate testing were included in a multivariate Cox regression model. A backward elimination procedure was used to exclude risk factors until the P-value of the likelihood ratio test for all remaining risk factors was ≤ .05. Success rates incorporating steroid doses at 6 months were calculated by multiplying FFS rates at 6 months and the proportion of patients taking the specified steroid doses at 6 months among those with FFS at 6 months. We selected graded prednisoneequivalent steroid doses of 0.3, 0.2 and 0.1 mg/kg/day as upper limits for these analyses. A dose of 0.3 mg/kg/day at 6 months approximates the 75th percentile dose (0.33 mg/kg/day). A dose of 0.2 mg/kg/day approximates the median at 6 months (0.22 mg/kg/day) and can be well tolerated for long periods of time in many patients, since prednisone doses less than 0.5 mg/kg every other day are well tolerated in our experience. 16, 19, 20 A dose of 0.10 mg/kg/day approximates the 25th percentile dose (0.09 mg/kg/day) and this dose also represents a desirable therapeutic goal in order to minimize steroid-induced complications in patients with rheumatologic diseases 21 or chronic GVHD. 22, 23 The analysis was carried out as of August 2012.
Results
Patient and GVHD characteristics
Patient characteristics are summarized in Table 1 . The median age of patients was 48 years (range, 1-73 years). Two hundred ten (67%) patients were prepared with high-intensity conditioning regimens, and 265 (85%) received mobilized blood cell grafts. The median time from transplantation to initial systemic treatment of chronic GVHD was 5.4 months (range, 2.2-
months).
GVHD characteristics are summarized in Table 2 . The median time from initial systemic For personal use only. on April 14, 2017. by guest www.bloodjournal.org From treatment to second-line treatment was 6.3 months (range, 0.2-61 months). The sites most frequently involved at the onset of second-line treatment were the skin (72%) and mouth (71%).
The NIH organ severity scores in each site are shown in Supplementary Figure S1 . Ninety-one (29%) patients had involvement of 4 or more sites, 128 (42%) had severe NIH global score, 54 (18%) had thrombocytopenia, 23 (7%) had hyperbilirubinemia, and 52 (17%) were receiving prednisone doses ≥ 1.0 mg/kg/day immediately before second-line treatment. The most frequently used second-line systemic treatments were mycophenolate mofetil (n=95), tacrolimus (n=63) and sirolimus (n=57). Thirty patients had second-line treatment within 1 month after initial treatment due to unequivocal progression in skin (n=7), liver (n=6), gastrointestinal tract with diarrhea (n=4), skin + eyes + mouth (n=1), skin + liver + diarrhea (n=1), and liver + diarrhea (n=1), or lack of improvement in skin (n=2), liver (n=4), skin + liver (n=1) and diarrhea (n=3). All 30 patients had moderate or severe global score and had received prednisone at doses ≥ 0.5 mg/kg/day immediately before second-line treatment.
Risk factors associated with treatment failure after second-line treatment
The FFS rate after second-line treatment was 56% (95% CI, 51-62%) at 6 months ( Figure 1 ).
Cumulative incidence estimates of failure at 6 months by cause were 34% for treatment change (onset of third-line treatment), 7% for nonrelapse mortality during second-line treatment, and 3% for recurrent malignancy during second-line treatment. Cumulative incidence estimates of successful withdrawal of all immunosuppressive agents during second-line treatment were only 1% at 6 months and gradually reached 15% at 48 months.
In univariate analysis (Table 3) , factors associated with increased risks of treatment failure included high-risk disease at transplantation, high-intensity conditioning with total body irradiation (TBI) as compared to high-intensity conditioning without TBI, lower gastrointestinal involvement at second-line treatment, >3 involved sites with chronic GVHD as compared to ≤ global score, thrombocytopenia, hyperbilirubinemia, and prednisone doses ≥ 1 mg/kg/day as compared to no prednisone immediately before second-line treatment. In multivariate analysis, 3 factors remained statistically significant: 1) high-risk disease at transplantation, 2) lower gastrointestinal involvement at second-line treatment, and 3) severe NIH global score at second-line treatment (Table 3) . Thrombocytopenia was dropped early from the model because it correlated with lower gastrointestinal involvement and prednisone dose.
Treatment failure rates according to risk groups
Treatment failure rates were analyzed for three risk groups categorized according to the total number of risk factors identified in the multivariate model ( Figure 2 ). This analysis excluded 4 patients who did not have information for NIH global severity score and 4 patients who had FFS at 6 months with information missing for steroid doses at 6 months. The low-risk group included 66 (22%) patients with no risk factor, the intermediate-risk group included 139 (46%) patients with 1 risk factor, and the high-risk group included 99 (33%) patients with 2 or 3 risk factors. As expected, failure rates were clearly stratified according to the three risk groups (P <.0001).
Cumulative incidence of successful withdrawal of immunosuppressive treatment according to steroid doses at 6 months
Steroid dose information at 6 months after second-line treatment was available in 170 of 174 patients who had FFS at 6 months. Among these patients, the median prednisone dose was 0.22 mg/kg/day (range, 0-2 mg/kg/day). Cumulative incidence estimates of successful withdrawal of all immunosuppressive agents during second-line treatment were compared according to various steroid dose limits at 6 months ( Figure 3) . The cumulative incidence of successful withdrawal was higher among patients taking prednisone-equivalent steroid doses Shorter-term success rates at 6 months according to risk groups Table 4 summarizes FFS rates at 6 months according to risk groups, since FFS is the metric of interest for future clinical trials. Among all patients, the FFS rate was 0.56 at 6 months. The 
Discussion
The current study offers several advances for studies evaluating treatment for chronic GVHD.
First, we show that FFS can serve as a meaningful endpoint for clinical trials. Second, we found that treatment change represented the predominant category of treatment failure, indicating that more efficient phase II trial design would be possible if treatment change were included as one type of failure in an FFS endpoint. Third, we identified 3 risk factors associated with failure and used them to stratify risk groups. Fourth, we found that lower steroid doses at 6 months were associated with higher rates of subsequent successful withdrawal of all immunosuppressive treatment during second-line treatment. Fifth, we report success rates accounting for both risk stratification at baseline and steroid dose limits at 6 months in order to make the endpoint more meaningful and to enhance the clinical benefit associated with the endpoint.
Our results showed that 34% of patients had second-line treatment failure at 6 months due to initiation of third-line treatment, which represented the predominant cause of treatment failure, and 7% had treatment failure due to nonrelapse mortality and 3% had treatment failure due to recurrent malignancy. Thus only 56% had FFS at 6 months. Treatment failure was predicted by 3 clinical factors: high-risk disease at transplantation, lower gastrointestinal involvement at second-line treatment, and severe NIH global score at second-line treatment. Patients without any risk factors had a 67% FFS rate at 6 months, whereas those with 2 or more risk factors had an FFS rate of 44% at 6 months. High-risk disease at transplantation appeared to be associated with all 3 components of failure (data not shown). Gastrointestinal involvement and severe NIH global score have been associated with increased risk of mortality in previous studies. [24] [25] [26] Describing the 3 causes of treatment failure helps to interpret the results of clinical studies.
For example, careful interpretation would be required if the results showed an increased risk of nonrelapse mortality or recurrent malignancy despite a reduced risk of treatment change. For this purpose, results shown in Figure 1 provide a useful point of comparison for future studies.
For personal use only. on April 14, 2017. by guest www.bloodjournal.org From Even for patients with FFS, the prolonged high-dose steroid exposure causes many adverse effects. 27 Therefore, it is important to consider steroid doses when the efficacy of second-line treatment is defined. The ability to control steroid-refractory chronic GVHD with reasonable doses of steroid is another important goal of second-line treatment. Our results showed that success endpoints incorporating a steroid dose limit at 6 months were associated with increased rates of subsequent withdrawal of all immunosuppressive treatment during secondline treatment, a long-term treatment goal that is usually not addressed in phase II trials. The choice of a dose limit to be used in defining success in future studies could depend on several factors, including patient characteristics, steroid doses administered at the onset of second-line treatment, and any expected steroid-sparing effects of the second-line agent. As in earlier studies, 15, 17, 25 ,28,29 we used withdrawal of all systemic immunosuppressive treatment without subsequent resumption for our analysis. Current immunosuppressive treatment-free survival could also be analyzed as an alternative approach to address the same question. 30 The eligibility criteria for the current study were carefully designed to represent the types of patients likely to be included in future clinical trials of second-line treatment for chronic GVHD, and all patients who met these criteria were included in the analysis. The minimum required duration of initial treatment before starting second-line treatment is somewhat shorter in our retrospective study than in previous prospective studies (2 weeks to 3 months). [31] [32] [33] [34] Our detailed review of each patient demonstrated a well justified rationale for second-line treatment even within 1 month after initial treatment in some patients. For this reason, we propose that similar patients could be considered as candidates for future clinical trials. Therefore, the results in Table 4 could be used in the design and interpretation of future phase II trials of second-line systemic treatment for chronic GVHD. As an example, if a presumed study cohort contains 70%
intermediate-risk patients and 30% high-risk patients, the probability of 6-month FFS with prednisone doses For 
